Alexis Borisy
About Alexis Borisy
Alexis Borisy, age 53, is the Lead Independent Director of Revolution Medicines (RVMD). He has served on the Board since November 2014 and presides over executive sessions of the Board, acting as a liaison between management and independent directors . He holds an A.B. in Chemistry from the University of Chicago and an A.M. in Chemistry and Chemical Biology from Harvard University, and is a veteran biotech company builder and venture investor .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| EQRx, Inc. | Executive Chairman | Sep 2021–Nov 2023 (acquired by RVMD Nov 2023) | Led board through acquisition; prior Chairman & CEO Aug 2019–Aug 2021 . |
| Third Rock Ventures | Partner | 2010–Jun 2019 | Company formation and venture leadership in biotech . |
| Blueprint Medicines (BPMC) | Interim CEO | 2013–2014 | Guided early-stage leadership; continuing director since 2011 . |
| Foundation Medicine | Co‑founder; Interim CEO | 2009–2011 | Foundational precision oncology platform leadership . |
External Roles
| Organization | Role | Public/Private | Tenure | Notes |
|---|---|---|---|---|
| Blueprint Medicines (BPMC) | Director | Public | Since 2011 | Co‑founder; ongoing board service . |
| Relay Therapeutics (RLAY) | Director | Public | Since Apr 2015 | Board member . |
| Tango Therapeutics (TNGX) | Director | Public | Since Mar 2017 | Board member; see RVMD–Tango collaboration below . |
| Nextech Invest | Chairman/Director | Private VC | Since 2022 | Chairman of the board . |
| OPKO Health (OPK) | Director (former) | Public | May 2022–Mar 2024 | Prior service ended 2024 . |
| Curie.Bio | Co‑founder; Operating Chairman | Private | Since 2022 | Company builder platform . |
| IDRx | Co‑founder | Private | Since 2022 | Oncology company formation . |
Board Governance
- Board class/tenure: Class III director; term expires at the 2026 annual meeting; director since 2014 .
- Independence: Board has determined Mr. Borisy is independent under Nasdaq rules; independent directors meet in regular executive sessions .
- Leadership: Serves as Lead Independent Director; presides executive sessions and liaises between management and the Board .
- Committees (current): Compensation Committee (member); Nominating & Corporate Governance Committee (member) .
- Committees (historical): Previously served on Audit Committee (per 2023 proxy) .
- Attendance: In 2024, the Board met 8x; each director attended at least 75% of Board and relevant committee meetings; all nine then‑serving directors attended the 2024 annual meeting . In 2022, Mr. Borisy attended all Board and relevant committee meetings (historical signal of engagement) .
- Committee composition context: Compensation Committee members in 2024 included Anderson (Chair), Borellini, Borisy, and (from Sep 2024) Clyburn; no interlocks disclosed .
Fixed Compensation
- Director cash fee schedule (2024 program):
- Annual base retainer: $45,000.
- Lead Independent Director fee: +$30,000.
- Committee fees (member/chair): Audit $10,000/$20,000; Compensation $7,500/$15,000; Nominating & Corporate Governance $5,000/$10,000; Research & Development $7,500/$15,000; Commercialization $7,500/$15,000 .
| 2024 Director Cash Fees (USD) | Amount |
|---|---|
| Fees Earned or Paid in Cash – A. Borisy | $87,349 |
Mix note: In 2024, Mr. Borisy’s cash represented ~14% of his total director compensation ($87,349 of $618,374); equity (options + RSUs) represented ~86% ($531,025), aligning pay with long-term value .
Performance Compensation
- Equity program (structure and vesting): Initial Grant at appointment = option to purchase 33,400 shares (monthly vesting over 3 years) + 9,600 RSUs (quarterly vesting over 3 years); Annual Grant at each annual meeting for continuing directors (pro‑rated if mid‑cycle) with options and RSUs; all vesting is service‑based (time‑based), not performance‑conditioned .
| 2024 Director Equity – A. Borisy | Amount/Terms |
|---|---|
| Stock Awards (RSUs) – grant date fair value | $159,470 |
| Option Awards – grant date fair value | $371,555 |
| Vesting Conditions | Time‑based per Director Compensation Program (options monthly; RSUs quarterly) |
| 12/31/2024 Outstanding Awards | 144,675 options; 4,248 RSUs |
Performance metrics: No performance‑based director equity metrics disclosed; director equity vests based on continued service, not on revenue/TSR/ESG targets .
Other Directorships & Interlocks
| Item | Details |
|---|---|
| Current public boards | BPMC (since 2011), RLAY (since Apr 2015), TNGX (since Mar 2017) . |
| Related‑party/Interlock | RVMD–Tango collaboration (Nov 2024 agreement; Apr 2025 project addendum) where Dr. Weber (RVMD director) is CEO/director of Tango and Mr. Borisy is a Tango director; Audit Committee approved under related person policy (> $120k anticipated cost of supplied materials) . |
| Transaction oversight | RVMD Board/Audit Committee policies require related party transactions >$120k to be reviewed for arm’s‑length terms; RVMD maintains indemnification and D&O insurance for directors . |
| EQRx acquisition | Mr. Borisy served as EQRx Executive Chairman and co‑founder; S‑4 disclosed he had financial interests that differed from other RVMD stockholders; RVMD Board considered these interests in approving the merger . |
Expertise & Qualifications
- Company builder and investor: co‑founded Foundation Medicine and Blueprint Medicines; long‑tenured venture partner at Third Rock Ventures .
- Multi‑company board experience across oncology/biotech, including BPMC, RLAY, TNGX; prior OPK board service .
- Academic credentials: A.B. in Chemistry (University of Chicago); A.M. in Chemistry and Chemical Biology (Harvard) .
Equity Ownership
| Beneficial Ownership as of 3/31/2025 | Shares/Percent |
|---|---|
| Outstanding shares beneficially owned | 2,331,494 |
| Shares exercisable within 60 days (vested options) | 128,720 |
| Total beneficially owned | 2,460,214 (1.3% of 186,258,206 shares outstanding) |
| Policy context | RVMD insider trading policy includes anti‑hedging and pledging provisions (alignment safeguard) . |
| Equity Positions Outstanding as of 12/31/2024 | Count |
|---|---|
| Options outstanding | 144,675 |
| RSUs outstanding | 4,248 |
Governance Assessment
-
Strengths
- Lead Independent Director with deep biotech formation and board experience; presides executive sessions, enhancing independent oversight .
- Active committee roles (Compensation; Nominating & Corporate Governance); historical Audit experience; attendance at/above norms (≥75% in 2024; 100% in 2022) .
- High ownership (1.3%), aligning interests with shareholders; director pay heavily equity‑weighted (~86%) .
-
Potential Risks / RED FLAGS (mitigations noted)
- Related‑party exposure via Tango Therapeutics collaboration (director at Tango; fellow RVMD director is Tango CEO); mitigated by Audit Committee approval under related person policy and ordinary‑course terms .
- EQRx acquisition conflict: disclosed differing financial interests given prior role/ownership; Board explicitly considered these interests in its fairness determination .
-
Overall View
- Governance profile is solid: independent leadership, meaningful skin‑in‑the‑game, established committee work, and transparent handling of interlocks/related‑party matters per policy. Continued monitoring is warranted around ongoing collaborations with companies where Borisy sits on the board, but current controls (Audit Committee review, disclosure) support investor confidence .